Palvella Therapeutics PVLA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.91M+157% | $2.59M+453% | $2.35M— | $1.91M— | $1.13M— | ||
| $28.1M+150% | $22.84M+180% | $18.26M— | $14.92M— | $11.24M— | ||
| $17.49M+95.0% | $15.76M+165% | $13.4M— | $11.63M— | $8.97M— | ||
| $45.59M+126% | $38.6M+174% | $31.66M— | $26.55M— | $20.21M— | ||
| -$45.59M-126% | -$38.6M-174% | -$31.66M— | -$26.55M— | -$20.21M— | ||
| —— | —— | $818K— | $764K— | $267K— | ||
| -$49.3M-114% | -$41.72M-139% | -$32.95M— | -$28.38M— | -$23.08M— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$49.3M-114% | -$41.72M-139% | -$32.95M-231% | -$28.38M-234% | -$23.08M-179% | ||
| -$4.17+41.7% | -$3.71+53.3% | -$2.63— | -$5.54— | -$7.15— | ||
| -$45.59M-126% | -$38.6M-174% | -$31.66M— | -$26.55M— | -$20.21M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Palvella Therapeutics's revenue?
- Palvella Therapeutics (PVLA) generated $40.9M in revenue over the trailing twelve months, up 142.9% year over year.
- Is Palvella Therapeutics profitable?
- Palvella Therapeutics is not currently profitable: it reported a net loss of $49.3M over the trailing twelve months, a 71.7% net margin.
- What is Palvella Therapeutics's earnings per share?
- Palvella Therapeutics's diluted EPS over the trailing twelve months is $-4.17.
- Where does Palvella Therapeutics's income statement data come from?
- Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
